GBM WHO CNS Grade 4 represents a major challenge for oncology due to its aggressive behavior. Conventional imaging has restrictions in detecting tumor recurrence. This prospective study aims to identify gene-based biomarkers in whole blood instead of isolating exosomes for the early detection of tumor recurrence. Blood samples (n = 33) were collected from seven GBM patients at time points before and after surgery as well as upon tumor recurrence. Four tumor tissue samples were assessed in parallel. Next-generation sequencing (NGS), including mRNA-seq and small RNA-seq, was used to analyze gene expression profiles in blood samples and tumor tissues. A novel filtering pipeline was invented to narrow down potential candidate genes. In total, between 6–93 mRNA and 1–19 small RNA candidates could be identified among the seven patients. The overlap of genes between the patients was minimal, indicating significant inter-individual variance among GBM patients. In summary, this prospective study supports the applicability of gene expression measurements in whole blood for the detection of tumor recurrence. It might provide an alternative to the challenging workflow of liquid biopsy after laborious exosome isolation from whole blood.
WHO中枢神经系统4级胶质母细胞瘤因其侵袭性行为成为肿瘤学领域的重大挑战。传统影像学技术在检测肿瘤复发方面存在局限。本前瞻性研究旨在通过全血基因检测而非外泌体分离技术，寻找基于基因的生物标志物以实现肿瘤复发的早期识别。研究从七名胶质母细胞瘤患者中采集了33份血液样本，取样时间点涵盖术前、术后及肿瘤复发阶段，并同步评估了四份肿瘤组织样本。采用包括mRNA测序和小RNA测序在内的新一代测序技术，对血液样本与肿瘤组织的基因表达谱进行分析。研究创新性地建立了筛选流程以缩小候选基因范围，在七名患者中共鉴定出6-93个mRNA候选基因及1-19个小RNA候选基因。患者间基因重叠率极低，表明胶质母细胞瘤患者存在显著的个体间差异。综上所述，本前瞻性研究证实了全血基因表达检测在肿瘤复发监测中的适用性，为替代当前需要从全血中费力分离外泌体的液体活检技术提供了新思路。
肿瘤(癌症)患者之家